journal
MENU ▼
Read by QxMD icon Read
search

Breast Cancer Research and Treatment

journal
https://www.readbyqxmd.com/read/29779072/intratumoral-heterogeneity-on-dedicated-breast-positron-emission-tomography-predicts-malignancy-grade-of-breast-cancer
#1
Norio Masumoto, Takayuki Kadoya, Shinsuke Sasada, Akiko Emi, Koji Arihiro, Morihito Okada
PURPOSE: Dedicated breast positron emission tomography (DbPET) provides detailed high-resolution images and can detect intratumoral heterogeneity using 18 F-fluorodeoxyglucose (FDG). We aimed to evaluate the correlation between FDG uptake on DbPET and the clinicopathological features of breast cancer, particularly those with an intratumoral heterogeneous distribution of FDG on DbPET. METHODS: We evaluated 195 consecutive patients with invasive breast cancer who underwent preoperative whole-body PET (WBPET) and DbPET concurrently between January 2016 and March 2017...
May 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29774471/age-at-first-full-term-birth-and-breast-cancer-risk-in-brca1-and-brca2-mutation-carriers
#2
Joanne Kotsopoulos, Jacek Gronwald, Henry T Lynch, Andrea Eisen, Susan L Neuhausen, Nadine Tung, Peter Ainsworth, Jeffrey N Weitzel, Tuya Pal, William D Foulkes, Charis Eng, Christian F Singer, Leigha Senter, Ping Sun, Jan Lubinski, Steven A Narod
PURPOSE: In the general population, an early age at first full-term birth confers protection against the risk of developing breast cancer. The relationship between age at first birth and breast cancer risk is not clear for women with a mutation in the BRCA1 or BRCA2 gene. Thus, we undertook a case-control study of women with a BRCA1 or BRCA2 mutation to study the effects of age at first full-term birth matched for other reproductive factors. METHODS: Information about reproductive factors, including age at first birth as well as medical history, was collected from a routinely administered research questionnaire...
May 17, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29774470/reproducibility-and-predictive-value-of-scoring-stromal-tumour-infiltrating-lymphocytes-in-triple-negative-breast-cancer-a-multi-institutional-study
#3
EDITORIAL
Mark O'Loughlin, Xavier Andreu, Simonetta Bianchi, Ewa Chemielik, Alicia Cordoba, Gábor Cserni, Paulo Figueiredo, Giuseppe Floris, Maria P Foschini, Päivi Heikkilä, Janina Kulka, Inta Liepniece-Karele, Peter Regitnig, Angelika Reiner, Ales Ryska, Anna Sapino, Aliaa Shalaby, Elisabeth Specht Stovgaard, Cecily Quinn, Elaine M Walsh, Vicky Zolota, Sharon A Glynn, Grace Callagy
BACKGROUND: Several studies have demonstrated a prognostic role for stromal tumour infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC). The reproducibility of scoring sTILs is variable with potentially excellent concordance being achievable using a software tool. We examined agreement between breast pathologists across Europe scoring sTILs on H&E-stained sections without software, an approach that is easily applied in clinical practice. The association between sTILs and response to anthracycline-taxane NACT was also examined...
May 17, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29767345/metastatic-breast-cancer-collateral-damage-project-mbccd-scale-development-and-preliminary-results-of-the-survey-of-health-impact-needs-and-experiences-shine
#4
Timothy J Williamson, Susan M Love, Jessica N Clague DeHart, Alexandra Jorge-Miller, Leah Eshraghi, Heather Cooper Ortner, Annette L Stanton
PURPOSE: Until recently, people with metastatic breast cancer (MBC) had a very poor prognosis. New treatment approaches have prolonged the time that people with MBC live, but their quality of life has received less attention. Consequently, the needs and concerns across financial, vocational, psychological, social, and physical domains in MBC patients are poorly understood-particularly regarding the collateral damage or longer-term, life-altering impacts of MBC and its treatments. This study's aims were to characterize MBC-related collateral damage, identify groups most likely to experience collateral damage, and examine its associations with psychological health, illness management, and health behaviors...
May 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29766363/palbociclib-in-highly-pretreated-metastatic-er-positive-her2-negative-breast-cancer
#5
G Hoste, K Punie, H Wildiers, B Beuselinck, I Lefever, E Van Nieuwenhuysen, S N Han, P Berteloot, N Concin, R Salihi, I Vergote, P Neven
PURPOSE: We aimed to investigate the role of palbociclib, a first-in-class cyclin-dependent kinase 4 and 6 inhibitor, in postmenopausal women with highly pretreated endocrine therapy-resistant metastatic breast cancer (MBC). METHODS: Between 28 September 2015 and 14 March 2017, a compassionate use program was established in the University Hospitals Leuven in which 82 postmenopausal women with estrogen receptor-positive, HER2-negative MBC were included after at least four lines of systemic treatment...
May 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29766362/exploration-of-tumour-infiltrating-lymphocytes-as-a-predictive-biomarker-for-adjuvant-endocrine-therapy-in-early-breast-cancer
#6
Erik J Blok, Charla C Engels, Geeske Dekker-Ensink, Elma Meershoek-Klein Kranenbarg, Hein Putter, Vincent T H B M Smit, Gerrit-Jan Liefers, James P Morden, Judith M Bliss, R Charles Coombes, John M S Bartlett, Judith R Kroep, Cornelis J H van de Velde, Peter J K Kuppen
PURPOSE: Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for endocrine therapy. EXPERIMENTAL DESIGN: The number of CD8-positive TILs was assessed in a subcohort of 236 patients in the Intergroup Exemestane Study. AQ After 2-3 years of adjuvant tamoxifen, AQpatients were randomized between the schemes of continuation for 5 years on tamoxifen and switching to exemestane...
May 15, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29766361/genetic-dissection-of-the-brca2-promoter-and-transcriptional-impact-of-dna-variants
#7
Eugenia Fraile-Bethencourt, Alberto Valenzuela-Palomo, Beatriz Díez-Gómez, Mar Infante, Mercedes Durán, Germán Marcos, Enrique Lastra, Susana Gómez-Barrero, Eladio A Velasco
PURPOSE: Promoter mutations may affect transcription and can be associated with human diseases. However, the promoters of the breast cancer (BC) genes are not regularly screened. Our goal was to investigate the BRCA2 promoter in order to study a possible correlation between impaired transcription and disease. METHODS: The proximal and core promoter of the BRCA2 gene was sequenced in 95 high-risk BC patients. A BRCA2-promoter insert [- 938 to + 312 from the transcription start site (TSS)] was generated and cloned into the firefly luciferase vector pGL4...
May 15, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29761323/effect-of-glucocorticoid-use-on-survival-in-patients-with-stage-i-iii-breast-cancer
#8
Ching-Hung Lin, Po-Ya Chuang, San-Lin You, Chun-Ju Chiang, Chiun-Sheng Huang, Ming-Yang Wang, Ming Chao, Yen-Shen Lu, Ann-Lii Cheng, Chao-Hsiun Tang
PURPOSE: Glucocorticoids (GCs) are commonly used in breast cancer patients to ameliorate emesis induced by chemotherapy. Some preclinical studies have suggested that systemic GCs might promote survival of estrogen receptor (ER)-negative breast cancer cells. This study aims to clarify their clinical effect on patient survival. METHODS: A total of 18,596 women with newly diagnosed stage I-III breast cancer in 2002-2006 were identified from the Taiwan Cancer Database and drug treatment was examined from the Taiwan National Health Insurance Claims Database...
May 14, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29761322/concurrent-risk-reduction-surgery-in-patients-with-increased-lifetime-risk-for-breast-and-ovarian-cancer-an-analysis-of-the-national-surgical-quality-improvement-program-nsqip-database
#9
Maryam Elmi, Arash Azin, Ahmad Elnahas, David R McCready, Tulin D Cil
BACKGROUND: Patients with genetic susceptibility to breast and ovarian cancer are eligible for risk-reduction surgery. Surgical morbidity of risk-reduction mastectomy (RRM) with concurrent bilateral salpingo-oophorectomy (BSO) is unknown. Outcomes in these patients were compared to patients undergoing RRM without BSO using a large multi-institutional database. METHODS: A retrospective cohort analysis was conducted using the American College of Surgeon's National Surgical Quality Improvement Program (NSQIP) 2007-2016 datasets, comparing postoperative morbidity between patients undergoing RRM with patients undergoing RRM with concurrent BSO...
May 14, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29754304/impact-of-high-deductible-insurance-on-adjuvant-hormonal-therapy-use-in-breast-cancer
#10
Christine Y Lu, Fang Zhang, Anita K Wagner, Larissa Nekhlyudov, Craig C Earle, Matthew Callahan, Robert LeCates, Xin Xu, Dennis Ross-Degnan, J Frank Wharam
OBJECTIVE: High-deductible health plans (HDHPs) have become the predominant commercial health insurance arrangement in the US. HDHPs require substantial out-of-pocket (OOP) costs for most services but often exempt medications from high cost sharing. We examined effects of HDHPs on OOP costs and utilization of adjuvant hormonal therapy (AHT), which are fundamental care for patients with breast cancer. METHODS: This controlled quasi-experimental study used claims data (2003-2012) from a large national health insurer...
May 12, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29752687/a-phase-ii-study-evaluating-the-efficacy-of-zoledronic-acid-in-prevention-of-aromatase-inhibitor-associated-musculoskeletal-symptoms-the-zap-trial
#11
Cesar A Santa-Maria, Aditya Bardia, Amanda L Blackford, Claire Snyder, Roisin M Connolly, John H Fetting, Daniel F Hayes, Stacie C Jeter, Robert S Miller, Anne Nguyen, Katie Quinlan, Gary L Rosner, Shannon Slater, Anna Maria Storniolo, Antonio C Wolff, Jane Zorzi, Nora Lynn Henry, Vered Stearns
PURPOSE: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a prospective clinical trial to evaluate whether bisphosphonates are associated with reduced incidence of AIMSS. METHODS: In the single-arm trial, the Zoledronic Acid Prophylaxis (ZAP) trial, we compared the incidence of AIMSS against historical controls from the Exemestane and Letrozole Pharmacogenomics (ELPh) trial...
May 11, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29752686/the-histone-deacetylase-inhibitor-obp-801-and-eribulin-synergistically-inhibit-the-growth-of-triple-negative-breast-cancer-cells-with-the-suppression-of-survivin-bcl-xl-and-the-mapk-pathway
#12
Hisako Ono, Yoshihiro Sowa, Mano Horinaka, Yosuke Iizumi, Motoki Watanabe, Mie Morita, Emi Nishimoto, Tetsuya Taguchi, Toshiyuki Sakai
PURPOSE: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Eribulin was approved for the treatment of metastatic breast cancer through the EMBRACE trial, and a subgroup analysis in this clinical trial indicated the efficacy of eribulin in patients with TNBC. However, the prognosis of patients with TNBC is still poor due to various molecular characteristics. Therefore, there is an urgent need for a more effective treatment for the management of TNBC...
May 11, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29748762/predictors-of-surveillance-mammography-outcomes-in-women-with-a-personal-history-of-breast-cancer
#13
Kathryn P Lowry, Lior Z Braunstein, Konstantinos P Economopoulos, Laura Salama, Constance D Lehman, G Scott Gazelle, Elkan F Halpern, Catherine S Giess, Alphonse G Taghian, Janie M Lee
PURPOSE: To identify predictors of poor mammography surveillance outcomes based on clinico-pathologic features. METHODS: This study was HIPAA compliant and IRB approved. We performed an electronic medical record review for a cohort of women with American Joint Committee on Cancer (AJCC) Stage I or II invasive breast cancer treated with breast conservation therapy who developed subsequent in-breast treatment recurrence (IBTR) or contralateral breast cancer (CBC)...
May 10, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29748761/gene-expression-in-triple-negative-breast-cancer-in-relation-to-survival
#14
Shuyang Wang, Alicia Beeghly-Fadiel, Qiuyin Cai, Hui Cai, Xingyi Guo, Liang Shi, Jie Wu, Fei Ye, Qingchao Qiu, Ying Zheng, Wei Zheng, Ping-Ping Bao, Xiao-Ou Shu
PURPOSE: The identification of biomarkers related to the prognosis of triple-negative breast cancer (TNBC) is critically important for improved understanding of the biology that drives TNBC progression. METHODS: We evaluated gene expression in total RNA isolated from formalin-fixed paraffin-embedded tumor samples using the NanoString nCounter assay for 469 TNBC cases from the Shanghai Breast Cancer Survival Study. We used Cox regression to quantify Hazard Ratios (HR) and corresponding confidence intervals (CI) for overall survival (OS) and disease-free survival (DFS) in models that included adjustment for breast cancer intrinsic subtype...
May 10, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29744676/associations-of-dietary-intake-and-supplement-use-with-post-therapy-cognitive-recovery-in-breast-cancer-survivors
#15
Zhezhou Huang, Yan Shi, Pingping Bao, Hui Cai, Zhen Hong, Ding Ding, James Jackson, Xiao-Ou Shu, Qi Dai
PURPOSE: Cognitive impairment induced by cancer therapy is common and can be long lasting after completion of therapy. Little is known on factors that influence recovery from the impairment. We evaluated the associations of dietary intake and supplement use with post-therapy cognitive recovery in a large cohort of breast cancer survivors. METHODS: This study included 1047 breast cancer patients aged 20-75 who were recruited to the Shanghai Breast Cancer Survival Study between 2002 and 2006 at approximately 6...
May 9, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29744675/treatment-induced-early-menopause-and-the-protective-role-of-gonadotropin-releasing-hormone-agonists-during-chemotherapy
#16
LETTER
Francesca Poggio, Benedetta Conte, Matteo Lambertini
No abstract text is available yet for this article.
May 9, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29744674/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-women-with-estrogen-receptor-positive-or-triple-negative-breast-cancer
#17
Aditya Bardia, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L Blackwell, Lisa A Carey, Joel R Eisner, Edwina S Baskin-Bey, Tiffany A Traina
PURPOSE: Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK), and activity of once-daily (QD) seviteronel in women with locally advanced or metastatic TNBC or ER+ breast cancer. METHODS: Seviteronel was administered in de-escalating 750, 600, and 450 mg QD 6-subject cohorts...
May 9, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29737474/incidence-and-risk-factors-for-congestive-heart-failure-in-patients-with-early-breast-cancer-who-received-anthracycline-and-or-trastuzumab-a-big-data-analysis-of-the-korean-health-insurance-review-and-assessment-service-database
#18
Jung Yoon Choi, Eun Young Cho, Yoon Ji Choi, Jeong Hyeon Lee, Seung Pil Jung, Kyu Ran Cho, Chul Yong Kim, Yeul Hong Kim, Kyong Hwa Park
PURPOSE: We aimed to analyze the incidence, time to occurrence, and congestive heart failure (CHF) risk factors for early breast cancer patients treated with anthracycline (AC)-based chemotherapy and/or trastuzumab (T) therapy in Korea. METHODS: We included female patients > 19 years old from the Health Insurance Review and Assessment Service database who had no prior CHF history and had been diagnosed with early breast cancer between January 2007 and October 2016...
May 8, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29737473/uptake-of-brca-1-2-and-oncotype-dx-testing-by-medical-and-surgical-oncologists
#19
Yonina R Murciano-Goroff, Anne Marie McCarthy, Mirar N Bristol, Peter Groeneveld, Susan M Domchek, U Nkiru Motanya, Katrina Armstrong
PURPOSE: The diffusion of genomic testing is critical to the success of precision medicine, but there is limited information on oncologists' uptake of genetic technology. We aimed to assess the frequency with which medical oncologists and surgeons order BRCA 1/2 and Oncotype DX testing for breast cancer patients. METHODS: We surveyed 732 oncologists and surgeons treating breast cancer patients. Physicians were from Florida, New York, New Jersey, and Pennsylvania, and were listed in the 2010 AMA Masterfile or identified by patients...
May 8, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29737472/snp-rs2071095-in-lincrna-h19-is-associated-with-breast-cancer-risk
#20
Ping Cui, Yanrui Zhao, Xinlei Chu, Na He, Hong Zheng, Jiali Han, Fengju Song, Kexin Chen
PURPOSE: An increasing number of long intergenic non-coding RNAs (lincRNAs) appear to play critical roles in cancer development and progression. To assess the association between SNPs that reside in regions of lincRNAs and breast cancer risk, we performed a large case-control study in China. METHODS: We carried out a two-stage case-control study including 2881 breast cancer cases and 3220 controls. In stage I, we genotyped 17 independent (r2  < 0.5) SNPs located in 6 tumor-related lincRNAs by using the TaqMan platform...
May 8, 2018: Breast Cancer Research and Treatment
journal
journal
28253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"